Kelvn | Istock | Getty Pictures
Shares of Japanese drugmaker Sumitomo Pharma fell over 12% Friday on what seemed to be profit-taking, a day after the federal government endorsed the corporate’s iPS cell-based remedy for Parkinson’s and coronary heart illness.
The choice is a milestone in Japan’s years-long effort to domesticate a homegrown sector targeted on cutting-edge mobile therapies.
Sumitomo Pharma’s inventory, which rose greater than 300% in 2025, hit its highest degree since 2019 final week amid rising confidence in its Parkinson’s remedy. The therapies depend on induced pluripotent stem (iPS) cells — grownup cells which might be reprogrammed again right into a stem-cell-like state.
“Whereas the therapy may doubtlessly see widespread use and grow to be a blockbuster in Japan and the US over the long run, we anticipate virtually no revenue contribution close to time period,” stated Citigroup World Markets Japan’s analyst Hidemaru Yamaguchi.
Sumitomo’s inventory has been overheated, and up to date positive aspects have been “extreme,” he added.
Based on Japan’s Ministry of Well being, Labor and Welfare, formal approval shall be granted throughout the subsequent one to 2 months, NHK reported.
The endorsement comes years after Kyoto College professor Shinya Yamanaka, who later received a Nobel Prize for his stem cell analysis, first succeeded in producing iPS cells from mice in 2006.
Sumitomo Pharma develops and markets prescription medicines throughout a number of therapeutic areas, together with neuroscience, oncology and regenerative medication.
